Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF

PHASE3CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

January 26, 2021

Primary Completion Date

January 2, 2024

Study Completion Date

February 22, 2024

Conditions
Short Bowel Syndrome
Interventions
DRUG

apraglutide

Apraglutide is a peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.

Trial Locations (68)

220

Far Eastern Memorial Hospital, New Taipei City

1062

Medical Centre, Hungarian Defence Forces, Budapest

1082

Semmelweis University, Budapest

1090

University Hospital Brussels, Brussels

2100

Rigshospitalet - University Hospital Copenhagen, Copenhagen

3000

Universitair Ziekenhuis Leuven - Gasthuisberg, Leuven

6017

Alesund Hospital, Ålesund

6202

Hôpital ARCHET II, Nice

6725

University of Szeged, Szeged

10029

Mount Sinai Medical Center, New York

10034

University Hospital Kralovske Vinohrady, 2nd Internal Clinic, Prague

10117

Charité - Universitätsmedizin Berlin, Berlin

10126

Citta della salute e della Scienza di Torino Hospital, Torino

12800

General University Hospital in Prague, Prague

19104

Hospital of the University of Pennsylvania, Philadelphia

20099

Asklepios Klinik St. Georg, Hamburg

27705

Duke University Hospital, Durham

28007

University General Hospital Gregorio Maranon, Madrid

28041

University Hospital 12 de Octubre, Madrid

30460

University Hospital Plzen, Pilsen

31096

Rambam Health Care Campus, Haifa

33604

Hôpital Haut-Lévèque, Pessac

34102

Gastroenterology Group of Naples, Naples

37212

Vanderbilt University Medical Center, Center for Human Nutrition, Nashville

40138

Polyclinic S. Orsola-Malpighi, Bologna

41013

University Hospital Virgen del Rocio, Seville

41345

Sahlgrenska University Hospital, Gothenburg

44093

CHU Hôtel Dieu, Nantes

44195

Cleveland Clinic Foundation, Cleveland

48149

University Hospital Muenster, Münster

48377

Henry Ford Medical Center - Columbus, Novi

49100

Rabin Medical Center, Petah Tikva

50005

University Hospital Hradec Kralove, Hradec Králové

53127

University Hospital Bonn, Bonn

54500

Brabois Adults Hospital, Vandœuvre-lès-Nancy

55905

Mayo Clinic, Rochester

60611

Northwestern University, Chicago

62500

University Hospital Brno, Brno

68198

University of Nebraska Medical Center, Omaha

69120

University Hospital Heidelberg, Heidelberg

69495

Hospices Civils de Lyon, Pierre-Bénite

90095

Ronald Reagan UCLA Medical Center, Los Angeles

92110

Hôpital Beaujon, Clichy

98195

University of Washington Medical Center, Seattle

5262000

Sheba Medical Center, Tel Litwinsky

45229-3039

Cincinnati Children's Hospital Medical Center, Cincinnati

Unknown

University Hospital Foundation Favaloro, Buenos Aires

University College Hospital, London

Salford Royal Hospital, Salford

741 01

Hospital Novy Jicin, Nový Jičín

H-1115

St. Imre University Teaching Hospital Budapest, Budapest

00168

"University Polyclinic Foundation Agostino Gemelli - IRCCS", Rome

05505

Yokohama Municipal Citizen's Hospital, Kanagawa

Asan Medical Center, Soeul

232-0024

Yokohama City University Medical Center, Kanagawa

980-8574

National University Corportation Tohoku University Tohoku University Hospital, Miyagi

565-0871

Osaka University Hospital, Osaka

169-0073

JCHO Tokyo Yamate Medical Center, Tokyo

85-391

Stadmedica, Non-Public Healthcare Facility, Bydgoszcz

80-152

COPERNICUS Limited Liability Company, Gdansk

90-531

M. Pirogow Provincial Specialized Hospital, Lodz

20-582

Gastromed Poland Sp. z o.o., Lublin

32-050

Stanley Dudrick Multispecialty Hospital, Skawina

06591

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

06351

Samsung Medical Center, Soeul

B15 2TH

University Hospitals Birmingham NHS Foundation Trust, Birmingham

HA1 3UJ

St Mark's Hospital, Harrow

E1 1BB

Royal London Hospital, London

All Listed Sponsors
lead

VectivBio AG

INDUSTRY

NCT04627025 - Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF | Biotech Hunter | Biotech Hunter